TY - JOUR T1 - A residual marker of cognitive reserve is associated with resting-state intrinsic functional connectivity along the Alzheimer’s disease continuum JF - medRxiv DO - 10.1101/2022.01.17.22269026 SP - 2022.01.17.22269026 AU - Ersin Ersoezlue AU - Robert Perneczky AU - Maia Tatò AU - Julia Utecht AU - Carolin Kurz AU - Jan Häckert AU - Selim Guersel AU - Lena Burow AU - Gabriele Koller AU - Sophia Stöcklein AU - Daniel Keeser AU - Boris Papazov AU - Marie Totzke AU - Tommaso Ballarini AU - Frederic Brosseron AU - Katharina Buerger AU - Peter Dechent AU - Laura Dobisch AU - Michael Ewers AU - Klaus Fliessbach AU - Wenzel Glanz AU - John Dylan Haynes AU - Michael T Heneka AU - Daniel Janowitz AU - Ingo Kilimann AU - Luca Kleineidam AU - Christoph Laske AU - Franziska Maier AU - Matthias H Munk AU - Oliver Peters AU - Josef Priller AU - Alfredo Ramirez AU - Sandra Röske AU - Nina Roy AU - Klaus Scheffler AU - Anja Schneider AU - Björn H Schott AU - Annika Spottke AU - Eike Jakob Spruth AU - Stefan Teipel AU - Chantal Unterfeld AU - Michael Wagner AU - Xiao Wang AU - Jens Wiltfang AU - Steffen Wolfsgruber AU - Renat Yakupov AU - Emrah Düzel AU - Frank Jessen AU - Boris-Stephan Rauchmann AU - DELCODE study group Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/19/2022.01.17.22269026.abstract N2 - Background Cognitive reserve (CR) explains interindividual differences in the impact of neurodegenerative burden on cognitive and daily functioning. A residual model was proposed to estimate CR more accurately compared to static measures, such as years of education. However, the functional brain correlates of residual CR markers (CRM) remain unexplored.Methods From the DELCODE cohort, 318 participants with resting-state functional and structural MRI data were included and stratified using cerebrospinal fluid (CSF) biomarkers according to the A(myloid-β, Aβ)/T(au)/N(eurodegeneration) classification scheme, resulting in 112 Aβ-negative healthy controls and 206 Aβ-positive patients in the Alzheimer’s disease (AD) spectrum.. CRM was calculated utilizing residuals obtained from a multilinear regression model using global cognition as dependent variable and demographic and disease burden measures as predictors. Associations between the CRM and intrinsic network connectivity (INC) in resting-state networks associated with cognition were explored, including the default mode network (DMN), frontoparietal network (FPN), salience network (SAL) and dorsal attention network (DAN). Moreover, the association between memory performance-associated regional INC and CRM was assessed.Results CRM was positively associated with INC in the DMN in the entire cohort. In a subgroup analysis, the A+T+N+ group revealed an anti-correlation between SAL and DMN. Furthermore, CRM was positively associated with the anti-correlation between the memory-related regions in the FPN and the DMN in the A+ and A+T/N+ subgroups.Conclusions CRM is associated with alterations of functional connectivity in resting-state networks of cognitive function, particularly the DMN and the FPN. Our results provide evidence on individual functional network differences associated with CRM in the AD continuum.Competing Interest StatementFrank Jessen received fees for consultation from Eli Lilly, Novartis, Roche, BioGene, MSD, Piramal, Janssen and Lundbeck. Josef Priller received fees for consultation, lectures and patents from Neurimmune, Axon, Desitin and Epomedics. Robert Perneczky received speaker honoraria and fees for consultation from Janssen, Roche, Biogen, Eli Lilly, Abbott, Schwabe and Grifols.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/29415768/ Funding StatementThe study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum fuer Neurodegenerative Erkrankungen (DZNE)), reference number BN012.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethical committees of the medical faculties of all participating sites: the ethical committees of Berlin (Charité, University Medicine), Bonn, Cologne, Goettingen, Magdeburg, Munich (Ludwig-Maximilians-University), Rostock, and Tuebingen. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn. The registration number of the trial at the ethical committee in Bonn is 117/13.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -